Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daxor Corporation filings document material events, capital-structure activity, governance votes, and regulatory disclosures for a Nasdaq-listed medical instrumentation and biotechnology company focused on blood volume measurement. Recent 8-K filings describe registered common-stock offerings, securities purchase and placement agency agreements, investor presentation materials, and the company’s common stock registration on Nasdaq.
The filing record also includes disclosures tied to FDA clearance for Daxor’s rapid, portable lab-based Blood Volume Analysis system, as well as annual meeting results covering director elections and auditor ratification. These documents frame the company’s formal reporting around BVA commercialization, financing, shareholder governance, and public-company compliance.
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
The award is contingent upon SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.
Daxor Corporation (DXR) filed a Form 4 on 26-Jun-2025 disclosing that director Caleb DesRosiers received 2,500 non-qualified stock options on 24-Jun-2025. The options carry an exercise price of $9.29 and expire on 24-Jun-2030. Vesting occurs in three installments: 833 options on 24-Jun-2025, 833 on 24-Jun-2026 and 834 on 24-Jun-2027. Following the grant, DesRosiers beneficially owns 2,500 derivative securities directly.
The award is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. No common-stock purchases or sales were reported, making this a routine compensation-related disclosure rather than a signal of insider sentiment.